AGL
agilon health, inc.
Next earnings Aug 3, 2026 · consensus $-0.11 EPS, $1.45B rev
Last earnings +4.2% on 2026-05-06
$111.01
▼ -3.60%$111.01▲ +92.23%
over 1Y
L $7.91H $119.25
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-3.6%
1W+3.5%
1M+28.0%
3M+933.6%
YTD+559.2%
1Y+92.2%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 21 analysts
Hold
Value-based care model is now loss-making at the gross line, revenue is shrinking, yet the stock trades at 8x sales — sell.
P/S (market cap / FY revenue) 8.1 · FY2025
agilon's core economics have inverted. Medical services expense rose to 101% of revenue in FY2025, so the company now spends more on care than it collects in capitation — gross profit swung to -$160.0M from +$4.8M in 2024, and non-GAAP medical margin flipped to -$56.6M from +$205.2M. Management attributes this to 'continued impact of elevated medical cost trends' (per-member medical cost up 5%) plus 'unfavorable prior period development' on risk-adjustment revenue. When a capitation business loses money on the medical line itself, the problem is structural, not a cost-control issue G&A can fix — and indeed G&A was already cut 11%. This is a deteriorating-fundamentals story across every lens.
The trend is the wrong direction on every axis. Revenue fell 2.1% to $5.93B as MA membership declined to 511,000 from 526,500 on partnership exits; net loss widened to -$391M, operating cash flow was -$106M, and Adjusted EBITDA deepened to -$296M from -$154M. The company has never earned a profit in the five years shown (FY2021–FY2025 all net losses), accumulated deficit is -$1.98B, and stockholders' equity has eroded to just $127M (-73% YoY), pushing liabilities/equity to 9.0x and ROE to -309%. Goodwill/intangible impairments jumped 903% to $36M and the CEO departed in 2025 — both signal management acknowledging the deterioration.
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 30, 2026, 12:48 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Is AGL a buy? The one-page verdict, explained →
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $1.52B | $2.39B | $4.32B | $6.06B | $5.93B |
| Gross profit | — | — | — | — | — |
| Operating income | -$372M | -$105M | -$232M | -$292M | -$463M |
| Net income | -$406M | -$107M | -$263M | -$260M | -$391M |
| Diluted EPS | — | — | — | — | — |
| Net margin | -26.7% | -4.5% | -6.1% | -4.3% | -6.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.71B
EV / EBITDA—
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-21.1%
FCF yield-6.4%
Quality & risk
ROIC (est.)-226.3%
Free cash flow-$119M
Total debt$35.0M
Net cash$139M
Altman Z-Score2.28 grey
Piotroski F-Score3/8
Capital returns
Buyback yield10.8%
Dividend yield (est.)—
Shareholder yield10.8%
Shares Δ YoY+0.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has skewed negative — read the flagged items.
- 8-K Shareholder vote2026-06-03
Annual meeting vote results certified (board, say-on-pay, auditor); routine governance
- 8-K Earnings results2026-05-06
Q1 2026 10-Q: revenue and margins still pressured by elevated medical costs
- 10-Q Quarterly report2026-05-06
Q1 2026 10-Q: revenue and margins still pressured by elevated medical costs
- 8-K Officer / director change2026-04-27
Executive leadership change (officer appointment/departure) plus Reg FD disclosure
- DEF 14A Proxy statement2026-04-22
Annual proxy: board slate, exec pay, auditor ratification for 2026 meeting
- 8-K Material event2026-03-30
Charter/bylaw amendment modifying shareholder rights; likely takeover-defense plan
- 8-K Shareholder vote2026-03-18
Special-meeting vote results plus other-event disclosure; routine governance
- 8-K Earnings results2026-02-25
FY2025: net loss $391M, gross loss, MA members down to 511K; medical margin negative
- 10-K Annual report2026-02-25
FY2025: net loss $391M, gross loss, MA members down to 511K; medical margin negative
Recent filings
all on EDGAR ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-06-012026-06-05open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗4Period ending 2026-06-022026-06-04open ↗8-KPeriod ending 2026-06-022026-06-03open ↗4Period ending 2026-05-242026-05-27open ↗SCHEDULE 13GFiling2026-05-14open ↗SCHEDULE 13GFiling2026-05-13open ↗
Frequently asked
- Is agilon health, inc. (AGL) a buy?
- AGL currently carries a Sell rating with 4/5 conviction, derived from its latest SEC filings. Value-based care model is now loss-making at the gross line, revenue is shrinking, yet the stock trades at 8x sales — sell.
- What is agilon health, inc.'s quality score?
- AGL scores 49.96695754682826/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001831097, latest 10-Q filed 2026-05-06) · EODHD · Proprietary analysis · as of 6/30/2026, 4:48:09 AM.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.